Renascience Cash Flow Statement

Financials in millions JPY. Fiscal year is April - March.

Millions JPY. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Net Income	-300	143	-256	-333	-253
Depreciation & Amortization	-	-	1	1	3
Loss (Gain) From Sale of Assets	-	1	4	-	11
Other Operating Activities	17	18	-1	-1	1
Change in Accounts Receivable	-	4	-4	-	-
Change in Accounts Payable	50	-10	26	67	-5
Change in Other Net Operating Assets	-58	-332	-	-18	13
Operating Cash Flow	-291	-176	-230	-284	-230
Capital Expenditures	-	-	-1	-2	-1
Investment in Securities	-	380	-	-	-
Other Investing Activities	-	2	-	2	1
Investing Cash Flow	-	382	-1	-	-
Long-Term Debt Issued	-	9	46	110	104
Long-Term Debt Repaid	-	-61	-	-	-380
Net Debt Issued (Repaid)	-	-52	46	110	-276
Issuance of Common Stock	1,894	-	-	-	1,868
Other Financing Activities	-	-	-	-	-1
Financing Cash Flow	1,894	-52	46	110	1,591
Miscellaneous Cash Flow Adjustments	-1	-1	-	-	-1
Net Cash Flow	1,602	153	-185	-174	1,360
Free Cash Flow	-291	-176	-231	-286	-231
Free Cash Flow Margin	-427.94%	-133.33%	-119.07%	-286.00%	-166.19%
Free Cash Flow Per Share	-22.60	-13.85	-18.17	-22.50	-20.28
Cash Interest Paid	-	-	-	-	4
Cash Income Tax Paid	45	2	1	1	-
Levered Free Cash Flow	-223.13	-98.88	-136.5	-159.75	-150
Unlevered Free Cash Flow	-223.13	-98.88	-136.5	-159.75	-146.88
Change in Working Capital	-8	-338	22	49	8